August 8, 2018—A new report by independent researchers refutes claims by the pharmaceutical industry that the 340B drug pricing program is so large it forces manufacturers to raise their prices. Writing in the Health Affairs Blog, a team of researchers from the Pew Charitable Trusts found the 340B program is only 1.4 percent of gross U.S. drug sales. This confirms earlier … [Read more...]